miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy
Biomolecules · 2025
DOI: 10.3390/biom15111499 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, 2025. Verfasst von Agata Kosmaczewska und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunopathology, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Scie…. Hauptthemen laut MEDLINE: MicroRNAs, Leukemia, Lymphocytic, Chronic, B-Cell, Receptors, Immunologic, T-Lymphocytes. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences, Wroclaw Medical University, Medical University of Lublin.
Abstract (Originalsprache)
Given that we have demonstrated that miR-155-5p is increased in CLL PBMCs and that its reduction with inhibitory siRNA partially restores the immune checkpoint BTLA protein level in CLL B cells, risk stratification for using anti-miR-155-based immunotherapy in CLL seems reasonable, particularly with its potential impact on T cells. Therefore, we aimed to assess the role of miR-155-5p in the epigenetic modification of BTLA levels in CLL T cells, especially since we observed that BTLA expression unfavorably promotes increased proliferative activity and IL-4 secretion in T cells, thus suggesting BTLA malfunction in the CLL T cell subset. Transfection of PBMCs with an inhibitor of miR-155-5p (INH) led to about a ten-fold down-regulation of miR-155-5p levels compared to control siRNA (NC) both in CLL patients and healthy individuals (HC), as assessed by RT-qPCR. Additionally, we did not find any significant differences in BTLA protein expression in T cells after silencing miR-155-5p in either examined group. We demonstrated for the first time that immunotherapy approaches based on systemic administration of anti-miR-155-5p therapeutics would be a favorable strategy in CLL, since they do not affect BTLA expression in T cell populations and could benefit CLL patients with impaired BTLA levels on CLL cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunopathology, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
- Laboratory of Genetics and Epigenetics of Human Diseases, Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 53-114 Wroclaw, Poland.
- Dental Center STOMO Clinic, 53-411 Wroclaw, Poland.
- Department and Clinic of Hematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University, 50-367 Wroclaw, Poland.
- Department of Clinical Immunology, Medical University of Lublin, 20-093 Lublin, Poland.
ORCID-Profile: Agata Kosmaczewska, Lidia Ciszak, Anna Andrzejczak, Anna Partyka, Zofia Rojek-Gajda, Agnieszka Bojarska-Junak, Jacek Roliński, Lidia Karabon
Förderung
- Hirszfeld Institute of Immunology and Experimental Therapy of the Polish Academy of Sciences
- Wroclaw Medical University
- Medical University of Lublin
Zitieren
APA
Kosmaczewska, A., Ciszak, L., Andrzejczak, A., Tomkiewicz, A., Partyka, A., Rojek-Gajda, Z., Frydecka, I., Wołowiec, D., Wróbel, T., Bojarska-Junak, A., Roliński, J., & Karabon, L. (2025). miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy. Biomolecules. https://doi.org/10.3390/biom15111499
Vancouver
Kosmaczewska A, Ciszak L, Andrzejczak A, Tomkiewicz A, Partyka A, Rojek-Gajda Z, et al. miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy. Biomolecules. 2025. doi:10.3390/biom15111499
BibTeX
@article{Kosmaczewska2025,
author = {Kosmaczewska, Agata and Ciszak, Lidia and Andrzejczak, Anna and Tomkiewicz, Anna and Partyka, Anna and Rojek-Gajda, Zofia and Frydecka, Irena and Wołowiec, Dariusz and Wróbel, Tomasz and Bojarska-Junak, Agnieszka and Roliński, Jacek and Karabon, Lidia},
title = {miR-155-5p Silencing Does Not Alter BTLA Molecule Expression in CLL T Cells: Implications for Targeted Immunotherapy},
journal = {Biomolecules},
year = {2025},
doi = {10.3390/biom15111499}
}
EUVIMED